Please login to the form below

Not currently logged in
Email:
Password:

Fasenra

This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ expects return to growth this year after 2017 decline

AZ brought five new medicines to market in 2017 - including new cancer medicines Imfinzi (durvalumab) and Calquence (acalabrutinib) as well as Fasenra (benralizumab) for asthma - and added new indications for Lynparza

Latest news

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics